Direct to consumer genetic testing: Avoiding a culture war

Genetics in Medicine

Volumn 11, Issue 8, 2009, Pages 568-569

  Evans, James P ^a   Green, Robert C ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; CLINICAL PRACTICE; CULTURAL FACTOR; GENETIC ANALYSIS; GENETIC ENGINEERING AND GENE TECHNOLOGY; GENETIC PROCEDURES; GENETIC RISK; GENOME ANALYSIS; MEDICAL INFORMATION; NOTE;

BIOMEDICAL RESEARCH; CONFIDENTIALITY; GENETIC COUNSELING; GENETIC TESTING; GENETICS, MEDICAL; HUMANS; INFORMATION DISSEMINATION; RISK ASSESSMENT; TECHNOLOGY TRANSFER;

EID: 69549122599     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181afbaed     Document Type: Note

References (14)

1. Hudson K, Javitt G, Burke W, Byers P. ASHG Statement* on direct-to-consumer genetic testing in the United States. Obstet Gynecol 2007;110:1392-1395. (Pubitemid 351326086)
2. Available at: http://www.dnapolicy.org/resources/DTCcompanieslist.pdf. Accessed May 22, 2009.
3. Lenfant C. Clinical research to clinical practice - lost in translation? N Engl J Med 2003;349:868-874.
4. Dawes RM, Faust D, Meehl PE. Clinical versus actuarial judgment. Science 1989;243:1668-1674.
5. McGuire AL, Burke W. An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA 2008;300:2669-2671.
6. Kraft P, Hunter DJ. Genetic risk prediction - are we there yet? N Engl J Med 2009;360:1701-1703.
7. Haynes RB, Mukherjee J, Sackett DL, Taylor DW, Barnett HJ, Peerless SJ. Functional status changes following medical or surgical treatment for cerebral ischemia. Results of the extracranial-intracranial bypass study. JAMA 1987;257:2043-2046. (Pubitemid 17056744)
8. Writing Group for the Women's Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-333.
9. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319.
10. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized european study. N Engl J Med 2009;360:1320-1328.
11. Hudson KL, Murphy JA, Kaufman DJ, Javitt GH, Katsanis SH, Scott J. Oversight of US genetic testing laboratories. Nat Biotech 2006;24:1083-1090.
12. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008;359:2208-2219.
13. Available at: http://www.genomeweb.com/dxpgx/23andme-adds-brca- breastovarian-cancer-testing-service?emc=el&m=315258&l=6&v= 1b456c9693. Accessed May 22, 2009.
14. Green R, Roberts J, Cupples L, et al. A randomized, controlled trial to evaluate the impact of APOE disclosure in relatives of patients with Alzheimer's disease: the REVEAL study. N Engl J Med In press.